A cannabis workshop on MEDICA’s November 16 sports-pharmacy agenda puts a practical question at the center of athlete care: how do professionals turn information about cannabinoids into a useful conversation? The published session is about counseling, rather than a promise that cannabis improves performance or recovery.

The official conference brochure schedules the workshop for 2:45 p.m. local time in Düsseldorf, Germany, during the sixth International Sports Pharmacy Symposium. Jeff Konin and Kari Franson are listed as speakers. The setting places cannabis alongside medication management, supplements and the responsibilities of athlete-support professionals.

The conversation comes before the recommendation

For a player, runner or recreational gym member, a cannabis question may begin with an ordinary concern: a product label, a teammate’s suggestion or uncertainty about a competition rule. Those starting points require different answers. A discussion of regulations cannot establish a health benefit, while a discussion of someone’s health cannot by itself settle eligibility.

That is what makes counseling a useful focus. The goal should be to establish what the person is asking, which product is involved and which rules apply. An answer about CBD cannot automatically be transferred to a preparation containing THC, and an answer for one sporting organization should not be presented as universal.

The symposium’s wider agenda includes supplement contamination, anti-doping work and professional ethics. Together, these subjects frame cannabis as one part of medication-related decision-making in sport. They do not turn a scheduled conference discussion into a new clinical finding or an endorsement of any product.

CBD and other cannabinoids are different questions

The U.S. Anti-Doping Agency’s cannabis guidance explains that cannabinoids are prohibited in competition under the World Anti-Doping Agency framework, with an exception for cannabidiol, or CBD. USADA also warns that the exception does not remove the risks associated with products sold as CBD.

That distinction is easy to lose in a broad conversation about cannabis becoming more accepted. Permission for one substance does not establish that every ingredient in a finished preparation is permitted. Nor does a label describing a product as hemp answer a question about its complete composition.

USADA’s separate CBD explainer emphasizes the potential for additional cannabinoids in products and the limitations of relying on a label. Athletes need to distinguish the status of CBD itself from the characteristics of the bottle, gummy or topical they are considering.

These are reasons to bring specific information to a qualified professional rather than ask only whether cannabis is allowed. The product, the sport and the athlete’s circumstances all shape the question. This preview does not recommend a dose, a preparation or a timetable for use.

Sports pharmacy is a developing professional skill

Franson’s institution, the USC Mann School, describes its executive sports-pharmacy certificate as preparation for advising athletes about medicines and nutritional supplements while addressing sporting rules. Its curriculum combines sports pharmacy, supplements, physical assessments and a focused thesis or experiential component.

The school currently lists a November 27 application deadline. That is a separate opportunity from attending the Düsseldorf symposium, with its own eligibility, cost and admissions requirements. Neither participating in a workshop nor completing an application should be confused with earning the certificate.

The curriculum’s patient-care approach includes collecting information, assessing it, planning, implementing and following up. Applied to a cannabis conversation, that suggests a more careful process than treating a social-media testimonial as a complete answer. It also leaves room to identify questions that require another professional’s expertise.

For example, a useful consultation can begin with the actual packaging and a clear account of what the athlete wants to understand. The professional can then identify whether the issue concerns ingredients, sporting rules or an individual health question. Keeping those questions distinct makes it easier to recognize the limits of an answer and what further information is needed.

Keep the November dates separate

The pharmacy symposium is on November 16. MEDICA’s Medicine + Sports Conference is separately listed for November 18–19. Visitors should check the correct program and access arrangements rather than assume a ticket or timetable covers every related event.

Our report on athletes and the 2027 anti-doping rules examines another part of this landscape. The Düsseldorf session offers a different angle: the professional conversation that helps an athlete interpret information before making a decision.

A workshop cannot settle every question about cannabis and sport in an afternoon. Its significance is more specific: a published sports-pharmacy program is making room for cannabis counseling alongside established concerns about medicines, supplements and clean competition. The useful outcome to watch is clearer communication, not a blanket claim that the plant belongs in every training plan.

Illustrative training-equipment photograph; not the MEDICA venue or workshop. Photo: Greg Rosenke / Unsplash.

Athletes have a cannabis rules change to prepare for in January, but the calendar matters as much as the ingredient. The World Anti-Doping Agency’s 2027 Prohibited List narrows its cannabinoid language while keeping THC and substances that mimic its effects prohibited in competition. The revision takes effect January 1, 2027; it is not permission to apply next year’s rules today.

For cannabis-aware sports readers, the important distinction is between a specific molecule’s status and a packaged product’s contents. A change involving CBN or CBG does not make every hemp extract, recovery supplement or bottle with a cannabis leaf on its label acceptable for an athlete subject to anti-doping rules.

A November 6 briefing from Ukraine’s National Anti-Doping Center highlights the cannabinoid revision among next year’s changes. Its guidance reinforces the distinction between THC-like substances and naturally occurring cannabinoids outside that description.

What changes in the new list

The 2027 list’s S8 section prohibits tetrahydrocannabinols and semi-synthetic or synthetic cannabinoids that mimic delta-9-THC’s effects in competition. Its examples include different THC forms and hexahydrocannabinol, commonly called HHC. Cannabidiol, or CBD, remains outside the prohibition.

UK Anti-Doping’s explanation specifically identifies cannabinol, or CBN, and cannabigerol, or CBG, as no longer prohibited under the 2027 revision. That is a meaningful change for people who follow the expanding vocabulary of cannabis ingredients. It is also narrower than announcing that cannabis itself has been removed from sport’s prohibited list.

WADA’s explanatory note ties the revision to scientific knowledge about cannabinoids with effects resembling delta-9-THC. The wording concerns the substances covered by the anti-doping category. It does not certify a manufacturer’s labeling or endorse a compound as a useful training aid.

November still belongs to the 2026 rules

Under the current framework, CBD is the cannabinoid exception; the broader cannabinoid prohibition still applies in competition. Athletes should not carry January’s revised ingredient treatment backward into a November event. A coach discussing next season and an athlete preparing for a competition this month may therefore need different editions of the list.

This is why a screenshot without a year can be misleading. Save the source, effective date and relevant section together. When asking a governing body about an ingredient, identify when the competition takes place and which rules govern it, rather than relying on an undated social post summarizing a future change.

Our coverage of Owen Trout’s rugby league case examined how THC rules can become consequential on match day. The new list offers another reason to distinguish an actual rule, its applicable period and an individual case rather than treating all sports cannabis stories as interchangeable.

A permitted ingredient is not a cleared product

The U.S. Anti-Doping Agency’s 2027 advisory stresses that athletes remain responsible for substances found in their samples. It also warns that CBD products may contain THC that is not clearly identified on a label. A permitted ingredient’s name on the front of a package cannot settle the contents of the entire mixture.

Think of the difference between asking whether CBG is prohibited and asking what is in a particular CBG product. The first is a rules question. The second involves the product itself. A correct answer to the first does not automatically resolve the second, especially when a formula combines multiple cannabis-derived ingredients.

Neither the revised list nor an ingredient exception establishes a medical benefit. Claims about sleep, recovery or performance require their own evidence. An athlete can misunderstand the update in two directions: by assuming every cannabinoid stays prohibited forever, or by interpreting a narrower prohibition as a broad wellness endorsement.

Use the update as a planning prompt

A useful next step for a competing athlete is to take the exact product and ingredient information to the appropriate anti-doping organization before making assumptions. USADA directs athletes to check medications through Global DRO and to recognize that prohibited lists are not exhaustive inventories of every possible substance name.

For coaches and support staff, the administrative task is straightforward: update educational materials with the January effective date, retain the current guidance for current competitions, and avoid advertising language that implies an entire product category has received approval. That communicates the change without exaggerating it.

The cannabis connection here is direct and practical. Sport is refining how it describes cannabinoids, while continuing to distinguish THC-related effects and competition restrictions. Understanding that refinement requires reading the year and the ingredient together, then keeping product claims separate from the rulebook.

Recreational spectators should also recognize the scope of the story. An anti-doping classification addresses eligibility and obligations within sport; it does not rewrite local cannabis law or a venue’s policies. An ingredient’s treatment in that system cannot establish where a person may purchase, carry or consume it. Keeping those questions separate helps a sports discussion remain accurate even when the same product appears in several different regulatory conversations.

The full official documents remain the reference point when abbreviated summaries leave an ingredient or a competition date unclear.

Illustrative stock photo of a track in Bielefeld, Germany; not a WADA event. Photo: Wilson K. / Unsplash.

Formula 1 heads to Interlagos for the São Paulo Grand Prix on November 6–8, with three practice sessions, qualifying and a Sunday race. For cannabis-aware sports followers, the weekend also offers a useful rules distinction: CBD’s exception under the World Anti-Doping Agency’s prohibited list does not make every cannabis-derived product suitable for a competing athlete.

That is educational context for following elite sport, not a suggestion that any driver uses cannabis or that a CBD product improves performance. The racing preview and the cannabinoid rules answer different questions. Understanding both helps keep sports coverage from treating a familiar wellness label as a blanket assurance.

The weekend schedule at Interlagos

Formula 1’s official event page confirms the São Paulo race at the Autódromo José Carlos Pace, commonly called Interlagos. The circuit measures 4.309 kilometers, with a scheduled 71-lap race. The venue’s world championship history dates to 1973, giving the modern event a long connection to Brazilian racing.

The Mercedes team’s event guide lists Friday practice at 12:30 p.m. and 4 p.m. São Paulo time, Saturday practice at 11:30 a.m. and qualifying at 3 p.m., and Sunday’s race at 2 p.m. Those are local track times, which matter when a website also displays a personalized time-zone view.

São Paulo is four hours ahead of Phoenix for this weekend. That places the scheduled race start at 10 a.m. Sunday in Arizona, with Saturday qualifying at 11 a.m. Phoenix time. Schedules remain subject to change, so a final check against official timing is sensible before arranging a watch party.

The Mercedes guide also recalls Ayrton Senna’s home victories in 1991 and 1993. That history helps explain why the venue matters beyond its dimensions and lap count. A race can be followed as a current sporting contest while also carrying memories for spectators whose attachment to the circuit predates today’s teams and drivers.

A full practice program changes the rhythm

The published 2026 program is a conventional Grand Prix format rather than a Formula 1 Sprint weekend. Friday’s two practice sessions and Saturday’s final session give the event a different structure from a program that compresses practice around a Sprint. References to a sprint in a support series should not be mistaken for an F1 Sprint session.

For spectators, that makes the distinction between session names useful. Practice offers preparation, qualifying establishes the starting order under the applicable rules, and the Grand Prix supplies the main race result. A fast practice lap should not be reported as pole position, and the weekend’s outcome cannot be inferred from an advance timetable.

Our Mexico City weekend preview covered the previous event’s setting. São Paulo is a separate race with its own program. This guide focuses on confirmed logistics and cannabis-related sporting context rather than unverified predictions about the championship.

CBD’s exception is specific

Under the 2026 WADA Prohibited List, cannabinoids are prohibited in competition, with cannabidiol, or CBD, identified as the exception. THC is included among the prohibited substances in that category. The list distinguishes an ingredient’s status; it does not approve every product sold under that ingredient’s name.

This is the point where consumer language and sporting obligations can diverge. A label emphasizing CBD can coexist with other cannabinoids in a formulation. An athlete needs to understand the actual product and the rules applicable to their competition, rather than assuming that a prominent front-label term settles the issue.

These anti-doping distinctions also do not establish what a spectator may bring into Brazil or into a particular venue. Sporting eligibility, national law, border requirements and event admission conditions are separate questions. Nothing in the race schedule or CBD exception should be read as a permission to carry cannabis to the circuit.

Why the product warning matters

UK Anti-Doping’s CBD advisory warns that products can contain other cannabinoids that are prohibited in competition. Its guidance highlights the difficulty of relying on a CBD product’s presentation as assurance about its contents. The permitted status of CBD itself therefore does not eliminate an athlete’s risk from a mixed or contaminated product.

For readers who train and compete, that is a practical distinction worth taking to the relevant anti-doping organization before making assumptions about a supplement. It is not a claim that all cannabis products have identical contents or that the same rules govern every person watching a race.

Interlagos provides the sporting occasion; the cannabinoid guidance supplies a precise cannabis connection. Follow the official timetable for the action, and keep the ingredient exception separate from claims about a branded product. Both habits favor the same thing: knowing what has actually been established before drawing a broader conclusion.

Stock motorsport photograph taken in 2025; not the 2026 São Paulo Grand Prix. Photo: Jonathan Borba / Pexels.